The antibody-based targeted delivery of TNF in combination with doxorubicin eradicates sarcomas in mice and confers protective immunity.
about
Immunocytokines and bispecific antibodies: two complementary strategies for the selective activation of immune cells at the tumor siteEvaluation of F8-TNF-α in Models of Early and Progressive Metastatic Osteosarcoma.TNFα sensitizes neuroblastoma cells to FasL-, cisplatin- and etoposide-induced cell death by NF-κB-mediated expression of Fas.The importance of Src signaling in sarcoma.MRI detection of breast cancer micrometastases with a fibronectin-targeting contrast agent.Immunocytokines for cancer treatment: past, present and future.Targeting cell death signaling in colorectal cancer: current strategies and future perspectives.Boosting the MHC Class II-Restricted Tumor Antigen Presentation to CD4+ T Helper Cells: A Critical Issue for Triggering Protective Immunity and Re-Orienting the Tumor Microenvironment Toward an Anti-Tumor State.Sarcoma Eradication by Doxorubicin and Targeted TNF Relies upon CD8+ T-cell Recognition of a Retroviral Antigen.Identification of a novel PD-L1 positive solid tumor transplantable in HLA-A*0201/DRB1*0101 transgenic miceThe antibody-mediated targeted delivery of interleukin-13 to syngeneic murine tumors mediates a potent anticancer activity.Preclinical evaluation of IL2-based immunocytokines supports their use in combination with dacarbazine, paclitaxel and TNF-based immunotherapy.Tumor-targeting properties of novel immunocytokines based on murine IL1β and IL6.Targeting Fibronectin for Cancer Imaging and Therapy.Intratumoral administration of IL2- and TNF-based fusion proteins cures cancer without establishing protective immunity.Novel antibody-cytokine fusion proteins featuring granulocyte-colony stimulating factor, interleukin-3 and interleukin-4 as payloads.Antibody-based delivery of tumor necrosis factor (L19-TNFα) and interleukin-2 (L19-IL2) to tumor-associated blood vessels has potent immunological and anticancer activity in the syngeneic J558L BALB/c myeloma model.Potency-matched Dual Cytokine-Antibody Fusion Proteins for Cancer Therapy.Addressing the Immunogenicity of the Cargo and of the Targeting Antibodies with a Focus on Demmunized Bacterial Toxins and on Antibody-Targeted Human Effector Proteins.Emerging classes of armed antibody therapeutics against cancer
P2860
Q28066935-A5F67CD2-62B0-4EC3-97D9-C3B7AAF559F2Q33607479-FDFB27BC-BF80-40F8-9448-8311D464E51CQ35609210-DE3C39CF-0460-4260-B346-EB48BF002F75Q35802929-313C5674-092D-40AC-AA22-2792BC6A1815Q36018529-48AC053D-8AAD-43A9-BCC4-87D8AF72FEEFQ37560208-290334A3-9321-494F-B301-D15503052E78Q37602717-28D46990-E7B9-46CC-93B6-EDA2A05D1D30Q38193821-4ECD6122-C627-4579-A4F9-575115777E82Q38704265-A86E6A45-F807-4D04-9C34-A229686E47F7Q38706572-41DDCBFF-E1C9-462D-9A02-4C7DFF0779E4Q38905573-42D2795D-C3A8-4CE7-A670-A3E0995974D8Q38988662-B4115B4D-0FCF-4756-8B1A-EA0EC5E5ABFBQ38998638-D24637F8-578C-4B4D-9408-0170551EBE02Q47226151-C7520B2E-FCE6-4089-BDD9-2B5F4D528FCCQ49687675-2CDA1091-ED8D-40FF-BB3B-6232F8488614Q50039410-60562733-0090-494D-BAB2-5C0AFD3894D9Q50073502-5DA9B3C8-4051-45F3-972B-2C0B2DCFC822Q50885364-E56C5D12-E6B3-4297-A418-907B42557752Q50962872-E2F2B4DB-8176-4DEA-ACAF-D29C03337109Q57911948-0372D0BE-32AC-436F-AAAC-5008F03881BA
P2860
The antibody-based targeted delivery of TNF in combination with doxorubicin eradicates sarcomas in mice and confers protective immunity.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 25 July 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The antibody-based targeted de ...... d confers protective immunity.
@en
The antibody-based targeted de ...... d confers protective immunity.
@nl
type
label
The antibody-based targeted de ...... d confers protective immunity.
@en
The antibody-based targeted de ...... d confers protective immunity.
@nl
prefLabel
The antibody-based targeted de ...... d confers protective immunity.
@en
The antibody-based targeted de ...... d confers protective immunity.
@nl
P2093
P2860
P356
P1476
The antibody-based targeted de ...... d confers protective immunity.
@en
P2093
P2860
P2888
P304
P356
10.1038/BJC.2013.421
P407
P50
P577
2013-07-25T00:00:00Z